불면증 환자 수 분석과 예측(2026-2035년)

Insomnia is a chronic sleep disorder characterized by persistent difficulty initiating sleep, maintaining sleep, or achieving restorative sleep despite adequate sleep opportunity. The condition is associated with impaired daytime functioning, reduced quality of life, increased healthcare utilization, and elevated risks of cardiovascular disease, depression, anxiety, and metabolic disorders. Patient population analysis provides valuable insights into disease prevalence, demographic distribution, diagnosis rates, treatment patterns, and future epidemiological trends that support market forecasting, clinical development, and healthcare planning.

Market Drivers

Increasing Prevalence of Chronic Insomnia

Changing lifestyles, rising stress levels, increasing mental health disorders, and an aging global population continue to increase the prevalence of chronic insomnia worldwide. Improved recognition of insomnia as a chronic medical condition is also contributing to higher diagnosis rates.

Growing Awareness of Sleep Health

Public health initiatives, physician education programs, and greater awareness of sleep disorders are encouraging earlier diagnosis and treatment. Routine screening in primary care settings is expanding the diagnosed patient population.

Aging Population

Older adults are more susceptible to insomnia because of age-related physiological changes, chronic illnesses, medication use, and sleep architecture alterations. The continued growth of the elderly population is expected to increase the global disease burden.

Increasing Burden of Mental Health Disorders

Insomnia frequently coexists with depression, anxiety, post-traumatic stress disorder, and other psychiatric conditions. Rising global mental health challenges continue to contribute to the expanding insomnia patient population.

Market Restraints

Underdiagnosis

A considerable proportion of individuals with insomnia remain undiagnosed because symptoms are often overlooked, self-managed, or attributed to lifestyle factors.

Variability in Diagnostic Practices

Differences in clinical guidelines, healthcare accessibility, and physician awareness contribute to inconsistent diagnosis rates across countries and healthcare systems.

Limited Access to Sleep Medicine Services

Many regions continue to face shortages of sleep specialists, sleep laboratories, and specialized diagnostic services, limiting early diagnosis and comprehensive patient management.

Patient Population Insights

The global insomnia patient population can be segmented by disease type, severity, age group, gender, diagnosis status, treatment status, and geography.

By disease type, the patient population includes acute insomnia and chronic insomnia. Chronic insomnia accounts for the majority of long-term healthcare utilization because of its persistent symptoms and associated comorbidities.

By severity, patients are categorized into mild, moderate, and severe insomnia, with severe disease requiring more intensive clinical intervention and long-term management.

By age group, the analysis covers pediatric, adolescent, adult, and geriatric populations. Adults and elderly individuals account for the largest share of diagnosed cases, while prevalence generally increases with advancing age.

By gender, insomnia affects both men and women, although women consistently exhibit higher prevalence than men across most age groups, influenced by hormonal, biological, and psychosocial factors.

By diagnosis status, the analysis evaluates diagnosed and undiagnosed patient populations, identifying opportunities to improve disease awareness and screening.

By treatment status, patients are classified into treated and untreated populations, highlighting the considerable unmet need for effective diagnosis and long-term management.

Epidemiology Trends

The global insomnia patient population continues to increase due to demographic, lifestyle, and healthcare changes.

Key trends include:

• Rising prevalence of chronic insomnia.
• Higher diagnosis rates through increased disease awareness.
• Growing disease burden among aging populations.
• Increasing association with anxiety, depression, and chronic medical conditions.
• Expansion of digital sleep health screening and wearable monitoring technologies.
• Improved epidemiological surveillance and real-world evidence generation.
• Greater emphasis on long-term disease management.

Regional Insights

North America represents one of the largest diagnosed insomnia patient populations owing to high disease awareness, advanced healthcare infrastructure, extensive sleep medicine services, and widespread screening programs.

Europe continues to report a significant disease burden supported by comprehensive healthcare systems, established epidemiological monitoring, and increasing recognition of insomnia as a chronic medical condition.

Asia-Pacific is expected to register the fastest growth in diagnosed patient numbers due to population aging, improving healthcare access, expanding sleep medicine services, increasing awareness, and rising healthcare investment across China, Japan, South Korea, India, and Australia.

Latin America and the Middle East & Africa are gradually improving diagnosis rates through healthcare modernization, enhanced physician education, and growing public awareness of sleep disorders.

Competitive Landscape

The insomnia patient population analysis supports pharmaceutical companies, biotechnology firms, healthcare providers, academic researchers, and policymakers in evaluating disease burden and identifying future commercial opportunities.

Organizations increasingly utilize epidemiological data to support clinical trial planning, patient recruitment, market forecasting, healthcare resource allocation, reimbursement planning, and commercialization strategies. Integration of electronic health records, digital health platforms, and real-world evidence is further strengthening patient population analysis.

Future Outlook

The global insomnia patient population is expected to continue expanding through 2035 due to aging populations, increasing mental health disorders, greater disease recognition, and improved access to healthcare services. Advances in artificial intelligence, wearable sleep monitoring, digital screening technologies, and population health analytics are expected to improve identification of undiagnosed patients while supporting earlier intervention and more personalized treatment approaches.

Continued investment in epidemiological research and real-world evidence will further improve understanding of disease burden and support healthcare planning worldwide.

Conclusion

The global Insomnia Patient Population Analysis highlights the increasing burden of insomnia worldwide and the growing number of individuals requiring diagnosis and long-term management. Rising prevalence, improved disease awareness, expanding healthcare access, and enhanced epidemiological surveillance are expected to drive continued growth in the diagnosed patient population. Although underdiagnosis and disparities in healthcare access remain important challenges, advances in sleep medicine, digital health technologies, and population analytics are expected to improve patient identification and treatment outcomes.

Key Benefits of this Report

• Comprehensive analysis of the global insomnia patient population and epidemiological trends.
• Detailed evaluation of prevalence, incidence, diagnosed, treated, and untreated patient populations.
• Assessment of demographic distribution by age, gender, disease severity, and geography.
• Insights into disease burden, unmet clinical needs, and future patient growth opportunities.
• Valuable resource for pharmaceutical companies, biotechnology firms, healthcare providers, researchers, investors, consultants, and policymakers.

What Businesses Use Our Reports For

Epidemiology forecasting, patient population estimation, clinical trial planning, market opportunity assessment, healthcare resource planning, investment analysis, commercialization strategy, reimbursement planning, and strategic decision-making.

Report Coverage

• Historical data from 2021 to 2025, Base Year 2025, and Forecast Period 2026 to 2035
• Comprehensive analysis of the global insomnia patient population by disease type, severity, age group, gender, diagnosis status, treatment status, and geography
• Evaluation of prevalence, incidence, diagnosed and undiagnosed populations, treated and untreated populations, and epidemiological trends
• Assessment of demographic characteristics, disease burden, healthcare utilization, and unmet clinical needs
• Analysis of regional epidemiology, patient growth trends, healthcare infrastructure, disease awareness initiatives, and future opportunities through 2035.

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Patient Population Landscape Overview
  • 1.1.1 Global Insomnia Patient Population Snapshot
  • 1.1.2 Addressable Patient Population Assessment
  • 1.1.3 Diagnosed versus Undiagnosed Population Analysis
  • 1.1.4 Treated versus Untreated Population Analysis
  • 1.1.5 Emerging Therapy-Eligible Patient Population
• 1.2 Key Strategic Insights
  • 1.2.1 Largest Opportunity Patient Segments
  • 1.2.2 High-Unmet-Need Population Clusters
  • 1.2.3 Emerging Therapy Adoption Potential
  • 1.2.4 Future Patient Population Shifts
  • 1.2.5 Key Growth Drivers
• 1.3 Key Conclusions
  • 1.3.1 Epidemiological Outlook
  • 1.3.2 Clinical Adoption Outlook
  • 1.3.3 Commercial Opportunity Outlook

2. Pipeline Overview

• 2.1 Global Insomnia Pipeline Landscape
  • 2.1.1 Active Pipeline Asset Inventory
  • 2.1.2 Historical Evolution of Insomnia Drug Development
  • 2.1.3 Emerging Therapy Development Trends
  • 2.1.4 Sponsor Participation Analysis
  • 2.1.5 Pipeline Maturity Assessment
• 2.2 Pipeline Composition Analysis
  • 2.2.1 Assets by Development Phase
  • 2.2.2 Assets by Mechanism of Action
  • 2.2.3 Assets by Modality
  • 2.2.4 Assets by Patient Population Focus
  • 2.2.5 Geographic Distribution of Clinical Development
• 2.3 Historical Progression Trends
  • 2.3.1 Historical Phase Advancement Trends
  • 2.3.2 Regulatory Approval Trends
  • 2.3.3 Clinical Attrition Trends
  • 2.3.4 Development Timeline Trends
  • 2.3.5 Sponsor Success Benchmarking

3. Disease and Unmet Need Analysis

• 3.1 Disease Overview
  • 3.1.1 Chronic Insomnia Disorder
  • 3.1.2 Acute Insomnia
  • 3.1.3 Comorbid Insomnia
  • 3.1.4 Treatment-Resistant Insomnia
  • 3.1.5 Special Population Insomnia
• 3.2 Epidemiology and Disease Burden
  • 3.2.1 Global Prevalence Analysis
  • 3.2.2 Incidence Trends
  • 3.2.3 Disease Burden Assessment
  • 3.2.4 Healthcare Utilization Impact
  • 3.2.5 Economic and Productivity Burden
• 3.3 Patient Journey Assessment
  • 3.3.1 Symptom Recognition Trends
  • 3.3.2 Diagnosis Pathways
  • 3.3.3 Treatment-Seeking Behavior
  • 3.3.4 Treatment Adherence Challenges
  • 3.3.5 Long-Term Disease Management Patterns
• 3.4 Unmet Need Assessment
  • 3.4.1 Undiagnosed Patient Population
  • 3.4.2 Untreated Patient Population
  • 3.4.3 Inadequately Controlled Population
  • 3.4.4 Relapsed and Refractory Patients
  • 3.4.5 High-Burden Population Segments

4. Mechanism and Modality Landscape

• 4.1 Mechanism of Action Clustering
  • 4.1.1 Dual Orexin Receptor Antagonists (DORAs)
  • 4.1.2 Selective Orexin Receptor Antagonists
  • 4.1.3 GABA-A Receptor Modulators
  • 4.1.4 Melatonin Receptor Agonists
  • 4.1.5 Circadian Rhythm Modulators
  • 4.1.6 Histaminergic Targets
  • 4.1.7 Serotonergic Targets
  • 4.1.8 Novel Mechanistic Approaches
• 4.2 Innovation Assessment
  • 4.2.1 First-in-Class Asset Assessment
  • 4.2.2 Best-in-Class Potential Assessment
  • 4.2.3 Clinical Differentiation Analysis
  • 4.2.4 Population-Specific Differentiation
  • 4.2.5 Precision Medicine Potential
• 4.3 Modality Analysis
  • 4.3.1 Small Molecule Therapeutics
  • 4.3.2 Biologics
  • 4.3.3 RNA-Based Therapeutics
  • 4.3.4 Cell Therapies
  • 4.3.5 Gene Therapies

5. Clinical Development Intelligence

• 5.1 Clinical Trial Landscape
  • 5.1.1 Active Clinical Trial Inventory
  • 5.1.2 Historical Trial Activity Trends
  • 5.1.3 Recruitment Activity Analysis
  • 5.1.4 Trial Completion Trends
  • 5.1.5 Planned Development Programs
• 5.2 Trial Design Benchmarking
  • 5.2.1 Sample Size Analysis
  • 5.2.2 Endpoint Benchmarking
  • 5.2.3 Trial Duration Benchmarking
  • 5.2.4 Comparator Selection Analysis
  • 5.2.5 Population Selection Benchmarking
• 5.3 Patient Population Benchmarking
  • 5.3.1 Adult Insomnia Population
  • 5.3.2 Elderly Population
  • 5.3.3 Pediatric Population
  • 5.3.4 Comorbid Insomnia Population
  • 5.3.5 Treatment-Resistant Population
• 5.4 Clinical Success Intelligence
  • 5.4.1 Success Rates by Phase
  • 5.4.2 Success Rates by Patient Segment
  • 5.4.3 Failure Drivers
  • 5.4.4 Recruitment Challenges
  • 5.4.5 Dropout Trends

6. Pipeline Segmentation Analysis

• 6.1 Pipeline by Development Phase
  • 6.1.1 Preclinical Pipeline
    • 6.1.1.1 Asset Inventory and Count
    • 6.1.1.2 Developer Analysis
    • 6.1.1.3 Mechanism Distribution
    • 6.1.1.4 Target Patient Populations
    • 6.1.1.5 Advancement Probability
  • 6.1.2 Phase I Pipeline
    • 6.1.2.1 Asset Inventory and Count
    • 6.1.2.2 Asset-Level Profiles
    • 6.1.2.3 Population Selection Analysis
    • 6.1.2.4 Early Safety Findings
    • 6.1.2.5 Advancement Probability
  • 6.1.3 Phase II Pipeline
    • 6.1.3.1 Asset Inventory and Count
    • 6.1.3.2 Asset-Level Profiles
    • 6.1.3.3 Proof-of-Concept Assessment
    • 6.1.3.4 Target Population Analysis
    • 6.1.3.5 Advancement Probability
  • 6.1.4 Phase III Pipeline
    • 6.1.4.1 Asset Inventory and Count
    • 6.1.4.2 Asset-Level Profiles
    • 6.1.4.3 Registrational Strategy Assessment
    • 6.1.4.4 Commercial Readiness Evaluation
    • 6.1.4.5 Approval Probability
  • 6.1.5 Filed and Under Review Assets
    • 6.1.5.1 Asset Inventory and Count
    • 6.1.5.2 Regulatory Status
    • 6.1.5.3 Approval Timeline Assessment
    • 6.1.5.4 Launch Readiness Evaluation
• 6.2 Pipeline by Mechanism of Action
  • 6.2.1 Orexin-Based Therapies
  • 6.2.2 GABAergic Therapies
  • 6.2.3 Circadian Rhythm Therapies
  • 6.2.4 Melatonin-Based Therapies
  • 6.2.5 Novel Mechanism-Based Therapies
• 6.3 Pipeline by Modality
  • 6.3.1 Small Molecules
  • 6.3.2 Biologics
  • 6.3.3 RNA Therapies
  • 6.3.4 Cell Therapies
  • 6.3.5 Gene Therapies
• 6.4 Pipeline by Patient Population
  • 6.4.1 Adult Population
  • 6.4.2 Elderly Population
  • 6.4.3 Pediatric Population
  • 6.4.4 Comorbid Insomnia Population
  • 6.4.5 Treatment-Resistant Population

7. Probability of Success and Risk Analysis

• 7.1 Phase Transition Probability Modeling
  • 7.1.1 Preclinical to Phase I
  • 7.1.2 Phase I to Phase II
  • 7.1.3 Phase II to Phase III
  • 7.1.4 Phase III to Approval
  • 7.1.5 Overall Approval Probability
• 7.2 Risk-Adjusted Pipeline Assessment
  • 7.2.1 Asset-Level Risk Scoring
  • 7.2.2 Mechanism-Based Risk Analysis
  • 7.2.3 Patient Population Risk Analysis
  • 7.2.4 Regulatory Risk Assessment
  • 7.2.5 Commercial Risk Assessment
• 7.3 Attrition Analysis
  • 7.3.1 Historical Attrition Trends
  • 7.3.2 Attrition by Development Phase
  • 7.3.3 Attrition by Mechanism
  • 7.3.4 Attrition by Population Segment
  • 7.3.5 Key Failure Drivers
• 7.4 Probability-Weighted Commercial Opportunity
  • 7.4.1 Risk-Adjusted Revenue Potential
  • 7.4.2 Population-Weighted Opportunity Assessment
  • 7.4.3 Peak Sales Probability Analysis
  • 7.4.4 Scenario-Based Forecast Modeling

8. Launch Timeline and Commercial Potential

• 8.1 Approval Timeline Forecasting
  • 8.1.1 Regulatory Submission Forecasts
  • 8.1.2 Approval Timeline Forecasts
  • 8.1.3 Launch Sequencing Analysis
  • 8.1.4 Competitive Entry Timing
• 8.2 Commercial Population Assessment
  • 8.2.1 Addressable Patient Population
  • 8.2.2 Eligible Patient Population
  • 8.2.3 Diagnosed Patient Population
  • 8.2.4 Treated Patient Population
  • 8.2.5 Therapy-Switch Population
• 8.3 Commercial Opportunity Analysis
  • 8.3.1 Population-Based Revenue Potential
  • 8.3.2 Adoption Potential by Segment
  • 8.3.3 Market Penetration Forecasts
  • 8.3.4 Peak Sales Potential

9. Competitive Pipeline Landscape

• 9.1 Company-Wise Pipeline Strength Assessment
  • 9.1.1 Leading Developers
  • 9.1.2 Challenger Companies
  • 9.1.3 Emerging Biotech Innovators
  • 9.1.4 Academic and Research Sponsors
• 9.2 Competitive Benchmarking
  • 9.2.1 Pipeline Breadth Assessment
  • 9.2.2 Pipeline Depth Assessment
  • 9.2.3 Population Coverage Benchmarking
  • 9.2.4 Innovation Leadership Analysis
• 9.3 Asset Concentration Analysis
  • 9.3.1 Top Assets by Commercial Potential
  • 9.3.2 Top Assets by Addressable Population
  • 9.3.3 High-Unmet-Need Population Assets
  • 9.3.4 White Space Opportunities

10. Geographic Analysis

• 10.1 North America
  • 10.1.1 Clinical Trial Activity
  • 10.1.2 Patient Population Trends
  • 10.1.3 Regulatory Environment
  • 10.1.4 Innovation Hubs
• 10.2 Europe
  • 10.2.1 Clinical Trial Activity
  • 10.2.2 Patient Population Trends
  • 10.2.3 Regulatory Environment
  • 10.2.4 Innovation Hubs
• 10.3 Asia-Pacific
  • 10.3.1 Clinical Trial Activity
  • 10.3.2 Patient Population Trends
  • 10.3.3 Regulatory Environment
  • 10.3.4 Innovation Hubs
• 10.4 Latin America
  • 10.4.1 Clinical Trial Activity
  • 10.4.2 Patient Population Trends
  • 10.4.3 Regulatory Environment
  • 10.4.4 Innovation Hubs
• 10.5 Middle East and Africa
  • 10.5.1 Clinical Trial Activity
  • 10.5.2 Patient Population Trends
  • 10.5.3 Regulatory Environment
  • 10.5.4 Innovation Hubs

11. Key Countries Analysis

• 11.1 United States
  • 11.1.1 Epidemiology Assessment
  • 11.1.2 Trial Activity
  • 11.1.3 Regulatory Timelines
  • 11.1.4 Key Sponsors
• 11.2 Canada
• 11.3 Germany
• 11.4 United Kingdom
• 11.5 France
• 11.6 Italy
• 11.7 Spain
• 11.8 China
• 11.9 Japan
• 11.10 India
• 11.11 South Korea
• 11.12 Australia
• 11.13 Brazil
• 11.14 Mexico
• 11.15 Saudi Arabia
• 11.16 South Africa

12. Deals and Investment Landscape

• 12.1 Licensing Activity
  • 12.1.1 Asset Licensing Trends
  • 12.1.2 Regional Licensing Activity
  • 12.1.3 Mechanism-Specific Licensing Trends
• 12.2 Strategic Collaborations
  • 12.2.1 Co-Development Agreements
  • 12.2.2 Research Collaborations
  • 12.2.3 Commercialization Partnerships
• 12.3 Mergers and Acquisitions
  • 12.3.1 Pipeline Asset Acquisitions
  • 12.3.2 Strategic Consolidation Trends
  • 12.3.3 Population Expansion Transactions
• 12.4 Funding Trends
  • 12.4.1 Venture Capital Activity
  • 12.4.2 Private Equity Activity
  • 12.4.3 Public Market Financing
  • 12.4.4 Funding by Development Stage

13. Future Outlook and Strategic Insights

• 13.1 Future Patient Population Dynamics
  • 13.1.1 Aging Population Impact
  • 13.1.2 Pediatric Opportunity Expansion
  • 13.1.3 Comorbidity-Driven Growth
  • 13.1.4 Precision Medicine Opportunities
• 13.2 Strategic Opportunity Assessment
  • 13.2.1 Undiagnosed Population Opportunities
  • 13.2.2 Untreated Population Opportunities
  • 13.2.3 High-Burden Population Opportunities
  • 13.2.4 White Space Opportunities
• 13.3 Long-Term Commercial Outlook
  • 13.3.1 Future Standard-of-Care Evolution
  • 13.3.2 Competitive Dynamics
  • 13.3.3 Future Commercial Leaders

14. Methodology and Data Framework

• 14.1 Research Methodology
  • 14.1.1 Pipeline Identification Framework
  • 14.1.2 Epidemiology Modeling Methodology
  • 14.1.3 Population Forecast Methodology
  • 14.1.4 Data Validation Framework
• 14.2 Data Sources
  • 14.2.1 ClinicalTrials.gov
  • 14.2.2 EU Clinical Trials Register
  • 14.2.3 Regulatory Filings
  • 14.2.4 Company Pipeline Disclosures
  • 14.2.5 Government Epidemiology Databases
  • 14.2.6 Peer-Reviewed Publications
• 14.3 Forecasting and Modeling Methodology
  • 14.3.1 Probability of Success Modeling
  • 14.3.2 Risk Adjustment Framework
  • 14.3.3 Epidemiology Forecasting Methodology
  • 14.3.4 Commercial Opportunity Modeling
• 14.4 Validation and Limitations
  • 14.4.1 Data Quality Assessment
  • 14.4.2 Assumptions Framework
  • 14.4.3 Model Limitations
  • 14.4.4 Verification Protocol